News
Guidance remains unchanged, with management projecting "over $100 million in partnership inflows by the end of 2026" and targeting a cash burn below $390 million in 2026. The company anticipates a ...
SALT LAKE CITY, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding ...
Zacks Investment Research on MSN2d
Recursion Pharmaceuticals to Report Q2 Earnings: What's in the Cards?Recursion Pharmaceuticals RXRX, a TechBio company that decodes biology and chemistry to industrialize drug discovery, is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback